Sleep Apnea Supportive Therapy Options Beyond CPAP

Sleep apnea supportive therapy refers to any treatment beyond continuous positive airway pressure (CPAP) that reduces the severity of obstructive sleep apnea or improves its downstream effects on health and quality of life. These approaches range from mouth guards and positional trainers to throat exercises, supplemental oxygen, weight-loss medications, and even wearable devices that vibrate when your oxygen drops. Some work well enough to replace CPAP for mild or moderate cases; others serve best as add-ons when CPAP alone falls short or when you simply cannot tolerate wearing a mask every night.

Positional Therapy

Many people with obstructive sleep apnea breathe far worse on their backs than on their sides. The airway is more prone to collapse when gravity pulls the tongue and soft tissue straight down. Positional therapy aims to keep you off your back during sleep, either with a wearable vibrating device, a specially shaped pillow, or older low-tech options like a tennis ball sewn into a shirt pocket on the back.

The evidence for newer-generation positional devices is strong for the right patients. A meta-analysis found that positional therapy cut the apnea-hypopnea index (AHI, the number of breathing disruptions per hour) by about 54% and reduced time spent sleeping on the back by roughly 84%.¹ Another analysis confirmed a similar magnitude of AHI reduction and also showed that the lowest overnight oxygen level improved by about 3%.² The catch is that positional therapy only helps people whose apnea is substantially worse on their back, a pattern sometimes called positional OSA. If your breathing disruptions are just as frequent on your side, keeping you off your back will not accomplish much.

Oral Appliances

Mandibular advancement devices (MADs) are custom-fitted mouthpieces that push the lower jaw forward during sleep, widening the space behind the tongue and reducing the likelihood of airway collapse. They look somewhat like orthodontic retainers and are fitted by dentists with training in sleep medicine.

Across multiple randomized trials involving patients with mild to severe sleep apnea, MADs reduced breathing disruptions by an average of about 55%, compared with roughly 83% for CPAP.³ CPAP is clearly the more powerful therapy on paper, but the real-world gap narrows because people tend to wear oral appliances more consistently. One crossover trial of patients with moderate to severe OSA found that reported nightly use averaged about 6.5 hours with an oral appliance versus 5.2 hours with CPAP.⁴ When you multiply a smaller per-hour benefit by more hours of actual use, the total overnight protection can be comparable.

Oral appliances are not a sure thing for everyone. Some patients get a large reduction in their AHI; others get very little. Jaw discomfort, changes in bite alignment over months or years, and excessive salivation are the most commonly reported drawbacks. Periodic dental check-ups are important to catch bite shifts early.

Myofunctional Therapy

Myofunctional therapy is essentially a structured exercise program for the tongue, soft palate, and throat muscles. The logic is straightforward: stronger, more toned airway muscles are less likely to collapse during sleep. The exercises typically involve tongue positioning drills, sustained vowel sounds, cheek resistance exercises, and swallowing patterns, performed for roughly 20 to 30 minutes a day over several months.

A systematic review and meta-analysis found that these exercises reduced the AHI by about 50% in adults and about 62% in children, while also improving oxygen levels, snoring, and daytime sleepiness.⁵ A Cochrane review found moderate-certainty evidence that the therapy reduces daytime sleepiness and low-certainty evidence of a large AHI reduction compared to sham exercises, though it noted the overall body of evidence is still limited in size.⁶

The biggest practical challenge is adherence. Unlike strapping on a device, oropharyngeal exercises require daily effort with no immediate feedback that they are working. Benefits tend to plateau after a few months of consistent practice, and it remains unclear how long the gains last if you stop. Still, for people with mild to moderate OSA who want to avoid devices entirely, or as a supplement alongside another therapy, the evidence suggests it is worth the effort.

Nasal Expiratory Positive Airway Pressure Devices

Nasal EPAP devices are small adhesive valves placed over each nostril at bedtime. They let you breathe in normally but create resistance when you exhale, building up pressure inside the airway that helps prop it open, a miniature, mask-free version of what CPAP does mechanically. The original brand-name product was Provent; similar devices have followed.

A randomized controlled trial found that nasal EPAP cut AHI by about 53% after one week and by about 43% after three months, with strong adherence: patients used the device for the entire night on roughly 88% of nights.⁷ Follow-up data at 12 months showed that these benefits were sustained, with continued improvement in daytime sleepiness and snoring for those who responded well early on.⁸ A separate study confirmed that about half of patients had an acceptable therapeutic response, and success was linked to the device actually generating and maintaining elevated pressure at the end of each breath.⁹

Because they are disposable, nasal EPAP devices have an ongoing per-night cost. They also do not work well for people who breathe primarily through the mouth, and nasal congestion can make them uncomfortable or ineffective. But for people who find CPAP intolerable and want something extremely simple, EPAP is a reasonable option, especially if a trial night in the sleep lab shows a good response.

Nocturnal Oxygen Therapy

Supplemental oxygen delivered by nasal cannula during sleep is sometimes used for sleep apnea, but its role is more nuanced than you might expect. A systematic review and meta-analysis found that nocturnal oxygen reduced the AHI by about 15 events per hour compared to sham air, and also modestly lowered both systolic and diastolic blood pressure over time.¹⁰ That sounds promising, but there is a wrinkle: oxygen can raise blood oxygen levels without eliminating the actual airway obstruction. An earlier meta-analysis noted that while oxygen improved saturation, the average duration of individual apnea and hypopnea events actually got longer in patients receiving oxygen compared to placebo.¹¹

What this means in practice is that oxygen can protect you from the blood-oxygen drops that cause the most immediate cardiovascular stress, but it may not resolve the repetitive arousals and sleep fragmentation that drive daytime fatigue. For this reason, nocturnal oxygen is typically considered a second-line or adjunctive therapy rather than a standalone fix, and it tends to be reserved for patients who also have significant heart or lung conditions layered on top of their sleep apnea.

Weight Loss and GLP-1 Receptor Agonists

Excess weight is the single most modifiable risk factor for obstructive sleep apnea. Fat deposits around the neck and tongue narrow the airway, and abdominal fat pushes the diaphragm upward, reducing lung volume. Research has consistently shown that the first 10% reduction in body mass index is associated with more than a 20% drop in AHI, regardless of how the weight is lost.¹²

The arrival of GLP-1 receptor agonist medications, drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), has reshaped the conversation around weight-related sleep apnea. These drugs produce substantially more weight loss than diet and exercise alone, and the downstream effects on breathing during sleep are now being quantified. One meta-analysis found that GLP-1 receptor agonist treatment reduced AHI by about 14 events per hour and body weight by roughly 12 kilograms compared to placebo, while also lowering systolic blood pressure.¹³ Another pooled analysis of trials in people without diabetes showed a slightly larger AHI reduction of about 17 events per hour.¹⁴

The primary mechanism here is straightforward: these drugs cause weight loss, and weight loss opens the airway. That said, the FDA granted approval for tirzepatide specifically for moderate-to-severe OSA in adults with obesity in late 2024, the first drug approved with that indication, signaling that pharmacologically driven weight loss is now a formally recognized treatment pathway. One important caveat is that AHI improvements depend on sustained weight loss. If the medication is discontinued and weight returns, the apnea typically worsens again.

Drugs That Target Airway Muscle Tone

A separate line of pharmacological research focuses on directly stiffening the airway muscles during sleep, rather than shrinking the tissue around them. The most studied approach combines a noradrenergic agent (which activates airway-dilating nerves) with an antimuscarinic agent (which blocks signals that relax those muscles). Various drug pairs have been tested, including atomoxetine plus oxybutynin and reboxetine plus oxybutynin.

A meta-analysis of eight randomized trials found that these combinations reduced AHI by about 9 events per hour and improved the lowest oxygen saturation by about 6 percentage points compared to placebo.¹⁵ The authors described the effect as “positive but modest.” Interestingly, a higher proportion of male participants was associated with a larger AHI reduction, suggesting that the drugs may work better in men, though the reason is not entirely clear.

None of these drug combinations are yet approved specifically for sleep apnea. They remain under investigation, and each comes with its own side-effect profile, including dry mouth, insomnia, and urinary retention from the antimuscarinic component. But for people whose apnea stems primarily from poor muscle tone rather than excess tissue bulk, this pharmacological approach addresses a root cause that CPAP, oral appliances, and weight loss do not.

Combining Therapies

Because different supportive therapies attack different aspects of airway collapse, combining them can produce results that exceed what any single approach achieves alone. This idea has been tested most rigorously with oral appliances plus positional therapy. In one study, patients with positional OSA started with a baseline AHI of roughly 21 events per hour. A mandibular advancement device alone brought it down to about 11, and positional therapy alone achieved a similar reduction. But using both together dropped the AHI to about 6, significantly better than either treatment on its own.¹⁶

A randomized controlled trial comparing the combination with each therapy used individually confirmed this pattern over six months. The combined approach yielded about a 72% AHI reduction, compared to roughly 44% for the oral appliance alone and 33% for positional therapy alone. The combination group also showed the best improvements in oxygen-related measures, and its treatment efficacy rate reached 80% versus 50% and 37% for oral appliance and positional therapy alone, respectively.¹⁷ The clinical takeaway is that if one supportive therapy gets you part of the way to an acceptable AHI, layering on a second may close the remaining gap without resorting to CPAP.

Fluid Shifts and Leg Compression

This is one of the more surprising corners of sleep apnea research. During the day, gravity pulls fluid into your legs. When you lie down at night, that fluid redistributes upward toward the neck and chest. In the neck, it can cause the airway tissues to swell slightly, contributing to obstruction. In the chest, it can trigger central apneas by affecting how the brain regulates breathing. The volume of fluid that shifts upward correlates with the severity of apnea.

Interventions that reduce daytime leg fluid accumulation, such as compression stockings, diuretics, physical activity, salt restriction, and dialysis in patients with kidney failure, have all been shown to reduce overnight fluid shift and lower apnea severity.¹⁸ This pathway is especially relevant for people with heart failure, kidney disease, or resistant hypertension, conditions where fluid overload is already a problem. For otherwise healthy individuals, the contribution of fluid shift to apnea is probably smaller, but wearing compression stockings during the day is a low-cost, zero-risk intervention that may offer a modest additional benefit.

Blood Pressure Effects of Supportive Therapies

Sleep apnea drives blood pressure up through repeated surges of stress hormones triggered by oxygen drops during the night. Any effective treatment should, in theory, bring blood pressure down. The data on CPAP’s blood pressure benefit has been somewhat disappointing for many patients, and supportive therapies provide an interesting comparison.

A large randomized trial compared mandibular advancement devices to CPAP head-to-head for blood pressure reduction. After six months, the oral appliance group saw a 2.5 mmHg decrease in 24-hour mean arterial blood pressure, while the CPAP group showed no significant change. The oral appliance was confirmed to be at least as good as CPAP for blood pressure, and the between-group difference favored the oral appliance, particularly for nighttime blood pressure readings.¹⁹ One likely explanation circles back to adherence: if patients wear the oral appliance for more hours per night, the total blood pressure benefit accumulates more.

GLP-1 receptor agonists also lower blood pressure, both through weight loss and through direct vascular effects. And nocturnal oxygen, as noted earlier, showed modest blood pressure reductions in the studies that tracked changes from baseline. The broader point is that cardiovascular protection does not require CPAP specifically; it requires effective treatment of the apnea and its metabolic consequences, and several supportive therapies deliver that.

Supportive Approaches in Children

Pediatric sleep apnea is most commonly caused by enlarged tonsils and adenoids, and the first-line treatment is surgical removal. But for children whose apnea persists after surgery, or whose anatomy is the primary issue, supportive therapies differ from the adult options. Rapid maxillary expansion, a palate-widening orthodontic device, has been studied as a treatment for children with sleep apnea linked to a narrow upper jaw. In one study, children who underwent rapid maxillary expansion achieved a mean expansion of about 4.3 millimeters and, at four months of follow-up, had an AHI below 1 event per hour, essentially a complete resolution of their apnea.²⁰

Myofunctional therapy also appears more effective in children than in adults, with one meta-analysis reporting a 62% AHI reduction in pediatric patients.²¹ Children’s airway tissues are more responsive to muscle toning, and addressing oral habits like mouth breathing, tongue thrusting, and low tongue posture early can influence how the jaw and airway develop over time. Pediatric sleep apnea treatment benefits from addressing anatomical growth rather than just compensating for existing obstruction.

Wearable Technology and Self-Guided Positional Training

Consumer wearable devices, including smart rings and fitness watches with pulse oximetry, are beginning to blur the line between clinical monitoring and active treatment. A recently reported case describes a patient who combined strict side-sleeping, head-of-bed elevation, and a consumer smart-ring oximeter that delivers a vibration when blood oxygen dips. Over several months, the patient maintained excellent adherence, lost a few pounds, and saw his Epworth Sleepiness Scale score drop from 11 (indicative of excessive daytime sleepiness) to 5 (normal range), with bed-partner-confirmed improvement in snoring.²²

A single case report is far from proof, but it illustrates where the field is heading. Clinical-grade positional trainers already use accelerometers and vibration motors to discourage supine sleep; the addition of real-time oxygen feedback from a consumer device adds a second layer of biofeedback. As these sensors grow more accurate and less obtrusive, the possibility of closed-loop supportive therapy, where the device detects a problem and nudges you into a better position before a full apnea event develops, moves closer to everyday reality. The regulatory and validation challenges are substantial, but the hardware is already in people’s homes.

Minor Surgical and Office-Based Procedures

Between the fully non-invasive world of mouthpieces and exercises and the major surgical realm of jaw advancement or tracheostomy, there exists a middle ground of office-based procedures that aim to reduce tissue bulk in the airway. Radiofrequency ablation of the soft palate and tongue base is one example. The procedure uses targeted heat to shrink and stiffen tissue, is performed under local anesthesia in an outpatient setting, and has been found to be a safe and effective option for properly selected patients with mild to moderate OSA who cannot tolerate or refuse CPAP.²³

These procedures tend to produce more modest AHI reductions than CPAP or oral appliances, and they may need to be repeated. Their greatest appeal is permanence relative to nightly devices: once the tissue is reduced, there is nothing to wear, charge, or replace. For patients with identifiable soft-tissue crowding and milder disease, an office-based procedure can shift them from a problematic AHI into a range where residual symptoms are minimal or manageable with a lighter-touch supportive therapy on top.